DrugPatentWatch Database Preview

Details for Patent: 6,335,369

Which drugs does patent 6,335,369 protect, and when does it expire?

Patent 6,335,369 protects CARNITOR and is included in one NDA.

This patent has four patent family members in four countries.

Summary for Patent: 6,335,369

Title:	Treating chronic uremic patients undergoing periodical dialysis
Abstract:	Chronic uremic patients undergoing periodical dialysis are treated with carnitine or one of its salts to prevent or treat carnitine deficiency in patients with end stage renal disease. An effective dose of carnitine, preferably L-carnitine fumarate, is administered preferably intravenously into the venous return line after each dialysis session.
Inventor(s):	Cavazza; Claudio (Rome, IT)
Assignee:	Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (Rome, IT)
Application Number:	09/761,639
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 6,335,369

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Leadiant Biosci Inc	CARNITOR	levocarnitine	INJECTABLE;INJECTION	020182-001	Dec 16, 1992	AP	RX	Yes	Yes	➤ Sign Up	➤ Sign Up				USE OF LEVOCARNITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 6,335,369

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
6,914,076	Treating chronic uremic patients undergoing periodical dialysis	➤ Sign Up
6,429,230	Treating chronic uremic patients undergoing periodical dialysis	➤ Sign Up
6,696,493	Treating chronic uremic patients undergoing periodic dialysis	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 6,335,369

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2381187	➤ Sign Up
European Patent Office	1257266	➤ Sign Up
Australia	3050201	➤ Sign Up
World Intellectual Property Organization (WIPO)	0152836	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 6,335,369

For more information try a trial or see the plans and pricing